AmideBio has leveraged its core manufacturing technology to pursue a series of therapeutic targets that include, ultrastable and ultraconcentrated insulin for T2 diabetes , glucose responsive insulin for T1 and T2 diabetes, solution stable glucagon for hyperinsulinism and similar orphan indications as well as the the development of diagnostics for early detection of T1 diabetes.
PROGRAM
INDICATION
DISCOVERY
PRECLINICAL
IND ENABLING
AB-SCI-0177
T2 DIABETES
AB-GLC-0035
HYPERINSULINISM
AB-GRI-0084
T1/T2 DIABETES
AB-DIG-0014
T1 DIAGNOSTIC